Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-γ agonism

Diabetes

Volumn 57, Issue 8, 2008, Pages 1999-2011

  Dallaire, Patrice ^a,b   Bellmann, Kerstin ^a,b   Laplante, Mathieu ^a,c   Gélinas, Stéphanie ^a,b   Centeno Baez, Carolina ^a,b   Penfornis, Patrice ^a,b   Peyot, Marie Line ^d   Latour, Martin G ^d   Lamontagne, Julien ^d   Trujillo, Maria E ^e   Scherer, Philipp E ^e,f   Prentki, Marc ^d   Deshaies, Yves ^a,c   Marette, André ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; ISOPHANE INSULIN; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN KINASE B; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; LIPID;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; GENOTYPE; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; INFLAMMATION; INSULIN SENSITIVITY; LIPID DIET; LIVER; LOW DRUG DOSE; MEDIATOR; METABOLIC ACTIVATION; MOUSE; NONHUMAN; OBESITY; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TISSUE METABOLISM; TRANSCRIPTION INITIATION; TREATMENT DURATION; WILD TYPE; ANIMAL; BLOOD; BODY WEIGHT; C57BL MOUSE; DRUG EFFECT; DRUG POTENTIATION; FAT INTAKE; FEMALE; GENETICS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; MALE; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

3T3-L1 CELLS; ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; BODY WEIGHT; DIETARY FATS; FEMALE; GENOTYPE; GLUCOSE TOLERANCE TEST; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SKELETAL; NITRIC OXIDE SYNTHASE TYPE II; OBESITY; PHOSPHORYLATION; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLIDINEDIONES;

EID: 50949133177     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db08-0540     Document Type: Article

References (55)

1. l.Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956, 1995
2. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 351:1106-1118, 2004
3. Bouskila M, Pajvani UB, Scherer PE: Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity? Int J Obes Relat Metab Disord 29 (Suppl. 1):S17-S23, 2005
4. Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M, Nawrocki AR, Rajala MW, Parlow AF, Cheeseboro L, Ding YY, Russell RG, Linde- mann D, Hartley A, Baker GR, Obici S, Deshaies Y, Ludgate M, Rossetti L, Scherer PE: A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145:367-383, 2004
5. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE: Structure-function studies of the adipocyte- secreted hormone Acrp30/adiponectin: implications for metabolic regulation and bioactivity. J Biol Chem 278:9073-9085, 2003
6. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME, Pang Z, Chen AS, Ruderman NB, Chen H, Rossetti L, Scherer PE: Mice lacking adiponectin show decreased hepatic insulin sensitivity and re- duced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 281:2654-2660, 2006 7. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE
7. Olefsky JM, Buchanan TA, Scherer PE: Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279:12152-12162, 2004
8. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, Hara K, Hada Y, Vasseur F, Froguel P, Kimura S, Nagai R, Kadowaki T: Impaired multim- erization of human adiponectin mutants associated with diabetes: molecular structure and multimer formation of adiponectin. J Biol Chem 278:40352-40363, 2003
9. Kahn BB, Alquier T, Carling D, Hardie DG: AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1:15-25, 2005
10. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95:2409-2415, 1995
11. Pickup JC, Mattock MB, Chusney GD, Burt D: NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleu- kin-6 with metabolic syndrome X. Diabetologia 40:1286-1292, 1997
12. Chinetti G, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49:497-505, 2000
13. Miles PD, Romeo OM, Higo K, Cohen A, Rafaat K, Olefsky JM: TNF-a- induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 46:1678-1683, 1997
14. Moller DE, Berger JP: Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord 27 (Suppl. 3):S17-S21, 2003
15. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macro- phage activation. Nature 391:79 -82, 1998
16. Maggi LB Jr, Sadeghi H, Weigand C, Scarim AL, Heitmeier MR, Corbett JA: Anti-inflammatory actions of 15-deoxy-S 12,14-prostaglandin J2 and trogli- tazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes 49:346-355, 2000
17. Pilon G, Dallaire P, Marette A: Inhibition of inducible nitric-oxide synthase by activators of AMP-activated protein kinase: a new mechanism of action of insulin-sensitizing drugs. J Biol Chem 279:20767-20774, 2004
18. Perreault M, Marette A: Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 7:1138-1143, 2001
19. Shimabukuro M, Ohneda M, Lee Y, Unger RH: Role of nitric oxide in obesity-induced beta cell disease. J Clin Invest 100:290-295, 1997
20. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH: Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad SciUSA 97:1784-1789, 2000
21. Bedard S, Marcotte B, Marette A: Cytokines modulate glucose transport in skeletal muscle by inducing the expression of inducible nitric oxide synthase. Biochem J 325:487-493, 1997
22. Kapur S, Bedard S, Marcotte B, Cote CH, Marette A: Expression of nitric oxide synthase in skeletal muscle: a novel role for nitric oxide as a modulator of insulin action. Diabetes 46:1691-1700, 1997
23. Noronha BT, Li JM, Wheatcroft SB, Shah AM, Kearney MT: Inducible nitric oxide synthase has divergent effects on vascular and metabolic function in obesity. Diabetes 54:1082-1089, 2005
24. Fujimoto M, Shimizu N, Kunii K, Martyn JA, Ueki K, Kaneki M: A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice. Diabetes 54:1340-1348, 2005
25. Sugita H, Fujimoto M, Yasukawa T, Shimizu N, Sugita M, Yasuhara S, Martyn JA, Kaneki M: Inducible nitric-oxide synthase and NO donor induce insulin receptor substrate-1 degradation in skeletal muscle cells. J Biol Chem 280:14203-14211, 2005
26. Engeli S, Janke J, Gorzelniak K, Bohnke J, Ghose N, Lindschau C, Luft FC, Sharma AM: Regulation of the nitric oxide system in human adipose tissue. J Lipid Res 45:1640-1648, 2004
27. Torres SH, De Sanctis JB, de L Briceno M, Hernandez N, Finol HJ: Inflammation and nitric oxide production in skeletal muscle of type 2 diabetic patients. J Endocrinol 181:419-427, 2004
28. Shibuya A, Wada K, Nakajima A, Saeki M, Katayama K, Mayumi T, Kadowaki T, Niwa H, Kamisaki Y: Nitration of PPARgamma inhibits ligand-dependent translocation into the nucleus in a macrophage-like cell line, RAW 264. FEBS Lett 525:43-47, 2002
29. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746-26749, 1995
30. Peyot ML, Nolan CJ, Soni K, Joly E, Lussier R, Corkey BE, Wang SP, Mitchell GA, Prentki M: Hormone-sensitive lipase has a role in lipid signaling for insulin secretion but is nonessential for the incretin action of glucagon-like peptide 1. Diabetes 53:1733-1742, 2004
31. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB III, Kaestner KH, Bartolomei MS, Shulman GI, Birnbaum MJ: Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292:1728-1731, 2001 32. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang CC, Itani SI, Lodish HF, Ruderman NB: Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP- activated protein kinase activation. Proc Natl Acad SciUSA99:16309 - 16313, 2002
32. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002
33. Park SH, Gammon SR, Knippers JD, Paulsen SR, Rubink DS, Winder WW: Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxy- lase in muscle. J Appl Physiol 92:2475-2482, 2002
34. Lessard SJ, Rivas DA, Chen ZP, Bonen A, Febbraio MA, Reeder DW, Kemp BE, Yaspelkis BB III, Hawley JA: Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance. Diabetes 56:1856-1864, 2007
35. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK: Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 272:5128-5132, 1997
36. Hu E, Kim JB, Sarraf P, Spiegelman BM: Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 274:2100-2103, 1996
37. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD: Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 11:861-866, 2005
38. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T: Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad SciUSA 102:9406-9411, 2005
39. Singh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298:1189-1195, 2007
40. Chakrabarti R, Vikramadithyan RK, Misra P, Hiriyan J, Raichur S, Damarla RK, Gershome C, Suresh J, Rajagopalan R: Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol 140:527-537, 2003
41. Cohen SE, Tseng YH, Michael MD, Kahn CR: Effects of insulin-sensitising agents in mice with hepatic insulin resistance. Diabetologia 47:407-411, 2004
42. Watkins SM, Reifsnyder PR, Pan HJ, German JB, Leiter EH: Lipid metabo- lome-wide effects of the PPARgamma agonist rosiglitazone. J Lipid Res 43:1809-1817, 2002 44. Wilson-Fritch L, Nicoloro S, Chouinard M, Lazar MA, Chui PC, Leszyk J, Straubhaar J, Czech MP, Corvera S: Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 114:1281-1289, 2004
43. Jiang G, Dallas-Yang Q, Li Z, Szalkowski D, Liu F, Shen X, Wu M, Zhou G, Doebber T, Berger J, Moller DE, Zhang BB: Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPAR--γ agonists. Diabetes 51:2412-2419, 2002
44. Hevener AL, He W, Barak Y, Le J, Bandyopadhyay G, Olson P, Wilkes J, Evans RM, Olefsky J: Muscle-specific Pparg deletion causes insulin resistance. Nat Med 9:1491-1497, 2003
45. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ, Reitman ML: Liver peroxisome proliferator- activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278:34268-34276, 2003
46. Kim JK, Fillmore JJ, Gavrilova O, Chao L, Higashimori T, Choi H, Kim HJ, Yu C, Chen Y, Qu X, Haluzik M, Reitman ML, Shulman GI: Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes 52:1311-1318, 2003
47. Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA: Peroxisome prolif- erator-activated receptor (PPAR) gamma: adipose-predominant expres-sion and induction early in adipocyte differentiation. Endocrinology 135: 798- 800, 1994 50. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, Flier JS: Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 99:2416-2422, 1997
48. Brun RP, Kim JB, Hu E, Spiegelman BM: Peroxisome proliferator-activated receptor gamma and the control of adipogenesis. Curr Opin Lipidol 8:212-218, 1997
49. Kondo E, Sugiyama T, Kusaka H, Toyoda N: Adiponectin mRNA levels in parametrial adipose tissue and serum adiponectin levels are reduced in mice during late pregnancy. Horm Metab Res 36:465-469, 2004
50. Rangwala SM, Rhoades B, Shapiro JS, Rich AS, Kim JK, Shulman GI, Kaestner KH, Lazar MA: Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. Dev Cell 5:657-663, 2003
51. Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, Abe Y, Funahashi T, Matsuzawa Y: Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94:e27-e31
52. Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME: Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 316:924-929, 2004
53. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y: Adiponec- tin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96:1723-1732, 2000
54. Thieringer R, Fenyk-Melody JE, Le Grand CB, Shelton BA, Detmers PA, Somers EP, Carbin L, Moller DE, Wright SD, Berger J: Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo. J Immunol 164:1046-1054, 2000
55. Sripalakit P, Neamhom P, Saraphanchotiwitthaya A: High-performance liquid chromatographic method for the determination of pioglitazone in human plasma using ultraviolet detection and its application to a pharma- cokinetic study. JChromatogrB Analyt Technol Biomed Life Sci 843:164-169, 2006